Centre for Health and Bioinformatics


Professor Anthony Moorman

Professor of Genetic Epidemiology


Roles and Responsibilities
  • Co-Director, Leukaemia Research Cytogenetics Group
  • Genetics lead, NCRI Childhood Cancer and Leukaemia Group (CCLG) Leukaemia Subgroup
  • Genetics lead, NCRI Haematological Malignancy Study Group - Adult ALL Working Party
  • Lead, Childhood Leukaemia sub-domain, Genomics England Haematology Malignancy Clinical Interpretation Partnership
  • Genetics co-ordinator for the following clinical trials – UKALL2011, UKALL14, UKALL60 , IntReALL2010

Area of expertise

  • Cancer genetics
Committee Membership
  • Bloodwise Childhood Leukaemia Cell Bank Steering Committee
  • NHS Southampton & SW Hampshire Local Research Ethics Committee (2003 - 2005)
  • International Membership of the American Society of Hematology
  • International BFM Study Group
Current Funding
  • EU Innovative Medicines Initiative (116026) Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in Hematology (HARMONY) 2016-2021. Lead: Jesús M Hernández; Participants leading on Childhood Leukaemia: Anthony Moorman, Dirk Reinhardt, Franco Locatelli. (Total Euro 20m)
  • Cancer Research UK 2016-2021. Personalising therapy for adults with acute lymphoblastic leukaemia. Anthony Moorman &  Adele Fielding (co-PIs), £2m
  • Bloodwise 2016-2021. Leukaemia Research Cytogenetics Group Specialist Programme. Anthony Moorman & Christine Harrison (co-PIs) £3m
  • Bloodwise Gordon Pillar Studentship 2016-2019 IKZF1 lesions in adult acute lymphoblastic lymphoma - the chicken or the egg? Adele Fielding (PI), Elli Papaemmanuil, Anthony Moorman. £148,596.00
  • Newcastle Healthcare Charity  2015-2016. Clinical evaluation of genetic biomarkers in childhood acute lymphoblastic leukaemia. Anthony Moorman & Christine Harrison. £19,623

Google Scholar: Click here.


The central philosophy of my research is based on the premise that the genetic heterogeneity of cancer is the key to furthering our understanding of the disease and to improving patient management and outcome. During my research career, I have focused on integrating high quality genetic information into the analysis of clinical trials and aetiological studies of acute leukaemia. Over the past 20 years, I have been involved in the development of an innovative research network which interfaces the Leukaemia Research Cytogenetics Group (LRCG) with clinicians, trial coordinators and geneticists. The establishment, maintenance and development of this innovative framework have enabled the curation and genetic annotation of samples from clinical trial patients diagnosed with acute leukaemia. Currently, the LRCG holds genetic, demographic and clinical data on more than 27,000 patients treated on over 15 National Cancer Research Institute (NCRI) clinical trials. This research infrastructure is unique because it encompasses two major haematological cancers (acute lymphoblastic and myeloid leukaemia) and is not restricted by the age of the patient.

We conduct comprehensive, pertinent and meticulous assessments of the clinical relevance of genetic markers within the context of national and international clinical trials. The objective is to provide clinicians with pertinent and reliable evidence to enable them to decide on the most effective course of treatment for their patients. The ultimate test of our work – at the interface between evidence-based genetic research and clinical practice - is its translational impact. Two major achievements with a direct impact on patient outcome have been: (1) the identification of a novel marker of poor outcome in childhood ALL [Blood, 2007, 109:2327]. This led directly to a protocol modification in the subsequent paediatric trial, so patients with this abnormality were transferred to the more intensive treatment arm. This change in treatment has reduced the risk of relapse in this subgroup of patients from >75% to <10%; (2) the comprehensive assessment of the clinical relevance of cytogenetics in adult ALL [Blood, 2007, 109:3189; Blood, 2009, 113:4489; Blood, 2009, 114:5136]. The results of this study led directly to patients with one of three chromosomal abnormalities being classified as high risk and treated differentially in the new adult ALL trial, UKALL14. The results of this study have also been used by other clinical groups to risk-stratify patients.


BSc in Biomedical Studies (Project Supervision)

MRes in Medical Sciences (Project Supervision)

MSc in Medical Sciences (Project Supervision & Medical Research in 21st Century Module)

PhD supervision

Research Student Development Programme ("Getting that first post-doc position" & "What makes a good poster?")